author-photo

Christopher Cannon

Regeneron

5

Papers

5

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN VERY HIGH RISK PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ANALYSES FROM THE ODYSSEY TRIALS

2017 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (1)
LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN WOMEN: ANALYSES FROM THE ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL

2017 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (0)
IMPACT OF STATIN INTOLERANCE RATES ON NEED FOR EZETIMIBE AND/OR PCSK9 INHIBITORS FOR MEETING LOW-DENSITY LIPOPROTEIN GOALS IN A REAL-WORLD COHORT WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

2017 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (1)
RELATIONSHIP BETWEEN MAJOR ADVERSE CARDIOVASCULAR EVENTS AND ACHIEVED LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PHASE 3 ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL

2016 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (2)
RELATIONSHIP BETWEEN PERCENTAGE REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AMONG PATIENTS TREATED WITH STATINS +/- ALIROCUMAB OR EZETIMIBE IN THE PHASE 3 ODYSSEY TRIALS

2016 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (1)